Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof

• US 20080038219A1
• Filed: 08/07/2007
• Published: 02/14/2008
• Est. Priority Date: 08/07/2006
• Status: Abandoned Application

• Current Assignee: Calgenex Corp. (Virtual Sourcing, Inc.)
• Original Assignee: Calgenex Corp. (Virtual Sourcing, Inc.)
• Inventors: Carlson, Grant, Mosbaugh, James
• Application Number:
  US11/835,213
• Publication Number:
  US 20080038219A1
• Time in Patent Office: Days
• US Class Current: 424/74
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 31/63 Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
• CPC Class Codes: A61K 31/7034 attached to a carbocyclic compound, e.g. phloridzin
• CPC Class Codes: A61K 36/81 Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 8/365 Hydroxycarboxylic acids; Ketocarboxylic acids
• CPC Class Codes: A61K 8/44 Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• CPC Class Codes: A61K 8/46 containing sulfur A61K8/44 takes precedence
• CPC Class Codes: A61K 8/466 containing sulfonic acid derivatives; Salts
• CPC Class Codes: A61K 8/63 Steroids; Derivatives thereof
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin

Abstract

A novel topical preparation comprised of carboxylic acids, chelating agents, dimethyl Sulfone and magnesium sulfate that forms a functional and versatile base formation for the addition of numerous medications and active ingredients for the purpose of treating certain skin conditions including, but not limited to psoriasis, eczema, dermatitis, acne, rosacea, scleroderma, skin stones, fungal infections, bacterial infections, or other skin disorders and diseases with improved efficacy and penetration

Claims

1. A formulation for a topical skin treatment that contains EDTA, Dimethyl Sulfone, citric acid, and magnesium sulfate within a stable emulsion wherein said EDTA is present at between 0.10% to 3% wt/wt %;

said Dimethyl Sulfone is present at between 0.20% and 15% wt/wt %;

said citric acid is present between 0.15% and 5% wt/wt %; and

said Magnesium Sulfate is present at between 0.10 and 10% wt/wt %, collectively contained within a topical formulation.

2. The combination of ingredients of claim 1 wherein said combination provides for enhanced penetration through the epidermis and delivery of magnesium and citrate ions into the dermis and hypodermis.

3. The combination of ingredients of claim 1 wherein said combination provides for the delivery of magnesium and citrate ions to the dermis and hypodermis to effective treat skin conditions.

4. The skin conditions of claim 3 that include psoriasis, dermatitis, eczema, and acne vulgaris.

5. The combination of the ingredients of claim 1 wherein said topical formulation is comprised of standard emollients, carrier oils binders, polymers, skin conditioners, skin protectants, oils, carriers, emulsifiers, preservatives, antioxidants, lubricating agents, and water in an oil in water emulsion.

6. The formulation of claim 5 wherein said topical formulation ingredients are comprised of Aloe Barbadensis, Butyrospermum Parkii (Shea Butter), Caprylyl Glycol, Carbomer, Cellulose Gum, Chamomilla Recutita (Matricaria) Flower Extract, Dimethicone Copolyol, Hexylene Glycol, Isopropyl Myristate, Phenoxyethanol Polysorbate 80, Potassium Sorbate, Propylene Glycol, Simmondsia Chinensis (Jojoba) Seed Oil, Tocopherol, Triethanolamine, Water.

7. The formulation of claim 1 wherein said formulation acts as enhanced base carrier for an antibiotic.

8. The antibiotics of claim 7 wherein said antibiotics are selected from the groups consisting of .beta.-lactam antibiotics, aminoglycoside antibiotics, tetracycline antibiotics, trimethoprim antibiotics, nitrofurantoin antibiotics and pharmaceutically acceptable salts thereof, and mixtures thereof.

9. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for an analgesic.

10. The analgesics of claim 9 wherein said analgesics are selected from the group consisting of methyl salicylate, menthol, camphor, eucalyptol, capsicum, oleoresin, chloroform, and derivatives and mixtures thereof.

11. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for a corticosteroids.

12. The corticosteroid of claim 11 wherein said corticosteroid is selected from the groups consisting of alclonetasone dipropionate, amcinonide, beclomethasone dipropionate, betamethasone, betamethasone 17-valerate, betamethasone 17,21-divalerate, betamethasone 21-acetate, betamethasone 21-butyrate, betamethasone 21-propionate, betamethasone 21-valerate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, cortexolone, corticosterone, cortisone, cortisone 17-acetate, 21-deoxybetamethasone, 21-deoxybetamethasone 17-propionate, deoxycorticosterone, desonide, desoxymethasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluclorolone acetonide, flumethasone pivalate, fluoconolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, 9-alpha-fluorocortisone, 9-alpha-fluorohydrocortisone, 9-alpha-fluoroprednisolone, fluprednidene acetate, flurandrenolone, halcinonide, hydrocortisone, hydrocortisone 17-acetate, hydrocortisone 17-butyrate, hydrocortisone 17-propionate, hydro cortisone 17-valerate, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, hydrocortisone 21-propionate, hydrocortisone 21-valerate, 17-alpha-hydroxyprogesterone, methylprednisolone acetate, mometasone furoate, prednisolone, prednisone, prednisone 17-acetate, prednisone 17-valerate, progesterone, triamcinolone, and trimcinolone acetonide. or acceptable salts thereof.

13. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for a nonsteroidal anti-inflammatory drug (NSAID).

14. The NSAIDs of claim 13 wherein;

said NSAIDs are selected from the group consisting of Indomethacin, Sulindac, Tolmetin, Piroxicam, Diclofenac potassium, Diclofenac sodium, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Etodolac, Aspirin, and Diflunisal and appropriate salts and mixtures thereof.

15. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for a zinc compound.

16. The zinc compounds of claim 15 wherein;

said zinc compounds are selected from the group consisting of zinc oxide, zinc sulfate, and acceptable salts thereof, and mixtures thereof.

17. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for an anti-fungal agent.

18. The antifungal agents of claim 17 wherein;

said antifungal agents are selected from the groups consisting of Clotrimazole, Miconazole, Butenafine, Naftifine, Ketoconazole, Ciclopirox, Terbinafine, Tolnaftate, Undecylenic acid and undecylenate salts (e.g., calcium undecylenate, copper undecylenate, zinc undecylenate), Sulconazole, sertaconazole, Econazole, boric acid, Ciclopirox olamine, Betamethasone, and acceptable salts or mixtures thereof.

19. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for coal tar.

20. The formulation of claim 1 wherein said formulation acts as a topical carrier formulation for salicylic acid.

21. The formulation of claim 1 wherein said formulation acts as a topical for at least one of an antibiotic, corticosteroid, non-steroidal antiinflammatory drug, zinc compound, analgesic compound or anti-fungal compound.

22. The composition of claim 1 wherein said formulation has a pH less between 5.00 and 5.50.

23. The composition of claim 1 wherein said formulation has a viscosity of between 12,000 and 13,000 centipoises

24. The composition of claim 1 wherein said formulation has a specific gravity of between 1.00 and 1.05.

25. The composition of claim 1 wherein said formulation has a specific gravity of 1.02.

26. The composition of claim 1 wherein said blend of EDTA, Dimethyl Sulfone, citric acid, and magnesium sulfate provides for enhanced penetration through the epidermis.

27. The composition of claim 1 wherein said blend of EDTA, Dimethyl Sulfone, citric acid, and magnesium sulfate provides for the delivery of magnesium cations and citrate anions to the dermis and hypodermis.

28. The composition of claim 1 wherein said topical preparation is applied to the body of a mammal to ease the suffering as caused by or to treat psoriasis including;

plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and erythrodermic psoriasis.

29. The composition of claim 1 wherein said topical is applied to the body of a mammal to ease the suffering due to or treat eczema or dermatitis, including atopic eczema, varicose eczema, discoid eczema, allergic contact dermatitis, irritant contact dermatitis, infantile seborrheic dermatitis, adult seborrheic dermatitis, atopic dermatitis, seborrheic dermatitis.

30. The composition of claim 1 wherein said topical formulation is applied to the body of a mammal to treat acne vulgaris, rosacea, scleroderma, skin stones, fungal infections, bacterial infections, or other skin disorders and diseases with improved efficacy and penetration.

31. The composition of claim 1 wherein said topical formulation is applied to the body of a mammal to treat itching as caused by irritation, bug bites, botanical irritants, poison oak, sumac.